Advertisement

Newborn Screening for Inborn Errors of Metabolism

  • Carol L. GreeneEmail author
  • Dietrich Matern
Chapter

Abstract

Newborn screening (NBS) is a system developed for early identification and treatment of newborns who have conditions for which treatment initiated in a timely fashion may prevent death or disability. Since public health departments began screening for phenylketonuria using blood collected on filter paper in the early 1960s, NBS has expanded to include other conditions, using a variety of analytical methods. This chapter focuses on NBS as blood spot screening of unselected newborns for evidence of inborn errors of metabolism. The principles considered here will also apply to NBS using blood spot samples for conditions other than IEM (including other genetic conditions such as cystic fibrosis or hemoglobinopathies and nongenetic conditions such as hypothyroidism and infections including HIV and CMV) and to some aspects of point-of-care screening (including hearing screening and pulse oximetry for critical congenital heart defects). In order for the practicing physician to be an effective partner in the NBS process, this chapter includes an overview of the history, evolving goals, principles, methodology, short- and long-term follow-up issues, and future challenges for NBS.

Keywords

Health Care Provider Inborn Error Congenital Hypothyroidism Maple Syrup Urine Disease Fatty Acid Oxidation Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. American Academy of Pediatrics Newborn Screening Authoring Committee (2008) Newborn screening expands: recommendations for pediatricians and medical homes – implications for the system. Pediatrics 121:192–217CrossRefGoogle Scholar
  2. American College of Medical Genetics Newborn Screening Work Group. ACMG ACT sheets and confirmatory algorithms. http://www.ncbi.nlm.nih.gov/books/NBK55829/. Accessed June 2013
  3. Andermann A, Blancquaert I, Beauchamp S, Dery V (2008) Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 86(4):317–319. doi: 10.2471/BLT.07.050112 PubMedCentralPubMedCrossRefGoogle Scholar
  4. Barker JM, Barriga KJ, Yu L et al (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89:3896–3902PubMedCrossRefGoogle Scholar
  5. Boneh A, Andresen BS, Gregersen N et al (2006) VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab 88(2):166–170PubMedCrossRefGoogle Scholar
  6. Brosco JP, Sanders LM, Dharia R et al (2010) The lure of treatment: expanded newborn screening and the curious case of histidinemia. Pediatrics 125(3):417–419PubMedCrossRefGoogle Scholar
  7. CDC (Domestic Public Health Achievements Team) (2011) Ten great public health achievements – United States, 2001–2010. MMMR Mortal Mon Rep 60:619–623Google Scholar
  8. Chen B, Gagnon M, Shahangian S et al (2009) Good laboratory practices for molecular genetic testing for heritable diseases and conditions. MMMR Mortal Mon Rep 58(RR6):1–37Google Scholar
  9. Choi JH, Velayati A, Stubblefield BK et al (2010) False-positive results using a Gaucher diagnostic kit – RecTL and N370S. Mol Genet Metab 100(1):100–102PubMedCentralPubMedCrossRefGoogle Scholar
  10. Comeau AM, Accurso FJ, White TB et al (2007) Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation Workshop Report. Pediatrics 119(2):e495–e518PubMedCrossRefGoogle Scholar
  11. Davis TC, Humiston SG, Arnold CL et al (2006) Recommendations for effective newborn screening communication: results of focus groups with parents, providers and experts. Pediatrics 117(5 Pt 2):S326–S340PubMedGoogle Scholar
  12. DeLuca JM, Kearney MH, Norton SA, Arnold G (2011) Parents’ experiences of expanded newborn screening evaluations. Pediatrics 128:53–61PubMedCrossRefGoogle Scholar
  13. Department of Health and Human Services (2013) Recommended uniform screening panel. http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendedpanel/index.html. Accessed June 2013
  14. Driscoll CJ, McPherson B (2010) Newborn screening: history, principles and analysis. In: Driscoll CJ, McPherson B (eds) Newborn screening systems: the complete perspective. Plural Publishing, San Diego/Abingdon/OxfordshireGoogle Scholar
  15. Hoffmann GF, Cornejo V, Pollitt R (2010) Newborn screening – progress and challenges. J Inherit Metab Dis 33(Suppl 2):S199–S200PubMedCrossRefGoogle Scholar
  16. Kemper AR, Boyle CA, Dougherte D et al (2008) Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Genet Med 10(4):259–261PubMedCrossRefGoogle Scholar
  17. Kronn D, Mofidi S, Braverman N, Harris K (2010) Diagnostic guidelines for newborns who screen positive in newborn screening. Genet Med 12:S251–S255. doi: 10.1097/GIM.0b013e3181fe5d8b PubMedCrossRefGoogle Scholar
  18. Maniatis AK, Taylor L, Letson GW et al (2006) Congenital hypothyroidism and the second newborn metabolic screening in Colorado, USA. J Pediatr Endocrinol Metab 19(1):31–38PubMedGoogle Scholar
  19. Maris JM, Woods WG (2008) Screening for neuroblastoma: a resurrected idea? Lance 371(9619):1142–1143CrossRefGoogle Scholar
  20. Riley RD, Burchill SA, Abrams KR et al (2003) A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing’s sarcoma and neuroblastoma. Health Technol Assess 7(5)Google Scholar
  21. Ross LF (2008) Newborn screening for cystic fibrosis: a lesson in public health disparities. J Pediatr 153(3):308–313PubMedCentralPubMedCrossRefGoogle Scholar
  22. Schmidt JL, Castellanos-Brown K, Childress S et al (2012) The impact of false-positive newborn screening results on families: a qualitative study. Genet Med 14(1):76–80PubMedCrossRefGoogle Scholar
  23. Schmidtke J, Cassiman J-J (2010) The EuroGentest clinical utility gene cards. Eur J Hum Genet 18(9):1. doi:10.1038/ejhg.2010.85. At http://www.eurogentest.org/professionals/public_health/info/public/unit3/geneCards.xhtml. Accessed Oct 2012Google Scholar
  24. Spiekerkoetter U, Haussmann U, Mueller M et al (2010) Tandem mass spectroscopy screening for very long-chain acyl-CoA dehydrogenase deficiency: the value of second-tier enzyme testing. J Pediatr 157(4):668–673PubMedCrossRefGoogle Scholar
  25. Tluczek A, Orland KM, Nick SW, Brown RL (2009) Newborn screening: an appeal for improved parent education. J Perinat Neonatal Nurs 23(4):326–334PubMedCentralPubMedCrossRefGoogle Scholar
  26. Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. WHO, Geneva. http://www.who.int/bulletin/volumes/86/4/07-050112BP.pdf. Accessed March 2013

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of MarylandBaltimoreUSA
  2. 2.Division of Laboratory Genetics, Departments of Laboratory Medicine and Pathology, Medical Genetics, and Pediatric and Adolescent MedicineMayo Clinic College of MedicineRochesterUSA

Personalised recommendations